Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

DUPIREAL, estudio en vida real de Dupilumab

¿En búsqueda del control a Largo plazo plazo en la RSCcPN grave? El Dr. Alejandro Motta describe el estudio DUPIREAL, evidencia reciente de Dupilumab en vida real.

Hexyon – nowa nazwa, te same wartości. Szczepienia 6w1 – nowe rekomendacje i możliwości

Zachęcamy do obejrzenia wykładu "Hexyon – nowa nazwa, te same wartości. Szczepienia 6w1 – nowe rekomendacje i możliwości", podczas którego wystąpili eksperci Dr n. med. Ilona Małecka oraz Prof. dr hab. n. med. Profesor Jacek Wysocki.

Dupixent wytyczne Euforea Pocket Guide 2025

Leki biologiczne w chorobach górnych i dolnych dróg oddechowych (opracowano na podstawie: Euforea Pocket Guide 2025)

Meningococcal ACWY Vaccines: Evolution from Polysaccharide to Conjugate Technology

Comprehensive overview of meningococcal vaccines targeting serogroups A, C, W, and Y, detailing the evolution from polysaccharide vaccines with limitations to superior conjugate vaccines. Includes clinical evidence of immunological hyporesponsiveness in polysaccharide vaccines and the dramatic disease reduction achieved through conjugate vaccine implementation, particularly in Africa's meningitis belt.

Conjugate vs. Polysaccharide: The Science Behind Better Meningococcal Protection

Comprehensive comparison between meningococcal conjugate and polysaccharide vaccines, highlighting the immunological advantages of conjugate vaccines including long-duration antibody response, memory B cell production, and herd immunity benefits. Essential information for healthcare providers, immunization specialists, and public health officials seeking evidence-based vaccine selection guidance.

IMD in South Africa: Provincial Analysis and National Trends

Current analysis of Invasive Meningococcal Disease (IMD) trends in South Africa, featuring provincial statistics, seasonal patterns, and mortality rates. Highlights significant 53% increase in cases from 2022 to 2023, with special focus on Western Cape's higher incidence rates and nationwide surveillance data from GERMS-SA programme.

Risk Factors for Meningococcal Disease: Understanding Carriage and Transmission

Comprehensive overview of risk factors associated with meningococcal carriage and disease transmission, including crowded living conditions, intimate contact, passive smoking, and travel to hyperendemic areas. Essential information for healthcare providers and individuals in high-risk settings such as university dormitories, military barracks, and laboratory environments.

IMD Survivor Complications

Comprehensive analysis of Invasive Meningococcal Disease (IMD) complications, featuring statistical data from an 868-case Canadian study. Details both neurological and non-neurological complications, including hearing loss, motor deficits, and skin scarring, while exploring the emotional and economic burden on families and caregivers.

Progression of IMD

Comprehensive guide to Invasive Meningococcal Disease progression, detailing the critical 24-hour timeline from initial flu-like symptoms to life-threatening complications. Essential information for healthcare professionals and concerned individuals about this rapidly progressing infection that requires urgent medical intervention.

Meningococcal Transmission and Carriage: Understanding the Path from Colonization to Disease

Comprehensive overview of Neisseria meningitidis transmission mechanisms, nasopharyngeal carriage, and progression to invasive disease. Features evidence-based information on transmission through respiratory droplets, carriage rates across populations, and the critical role of carriage in disease spread, with special focus on high-risk groups like university students and military personnel.

Part 1 of 10: What advantages does Toujeo (insulin glargine 300 U/mL) offer over older basal insulins

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

SULIQUA - Uproszczenie Schematu Leczenia Cukrzycy.

Zapraszamy do zapoznania się z materiałem prezentującym SULIQUA® - innowacyjne rozwiązanie w leczeniu cukrzycy typu 2. Dowiedz się, jak można uprościć schemat leczenia, poprawić kontrolę glikemii i zredukować ryzyko hipoglikemii przy jednym wstrzyknięciu dziennie. Materiał zawiera kluczowe informacje o skuteczności terapii i jej wpływie na jakość życia pacjentów.